Merdury
水星生醫股份有限公司
Merdury is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is 武倍威剛口溶錠50毫克 (TFDA marketing authorization obtained), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| 武倍威剛口溶錠50毫克 | — | TFDA marketing authorization obtained | — | — | 2026-01-19 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.